© 2003 European Society of Cardiology
Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography
a Department of Medicine and Therapeutics, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK
b Department of General Practice Leicester LE2 7LX, UK
c Department of Epidemiology, University of Leicester Leicester LE2 7LX, UK
d Department of Cardiology, Glenfield Hospital Leicester LE2 7LX, UK
* Corresponding author. Tel.: +44-0116-252-3132; fax: +44-0116-252-3108 E-mail address: lln1{at}le.ac.uk
 |
Abstract |
|---|
Aims: We examined strategies to improve the positive predictive value of natriuretic peptides in screening for undiagnosed left ventricular systolic dysfunction (LVSD) in the community. Methods and results: The value of B-type(BNP), N-terminal proB-type (N-BNP) and N-terminal proAtrial(N-ANP) natriuretic peptides was prospectively assessed in 1360 subjects (45–80 years) together with echocardiography and electrocardiography. Seventeen individuals had definite and 13 had borderline, LVSD. Receiver-operating-characteristic (ROC) curve analysis showed the superiority of BNP (ROC areas 0.942 for definite LVSD, P<0.03; 0.934 for borderline LVSD, P<0.003) compared to N-BNP or N-ANP. Peptide levels, major ECG abnormality and ischaemic heart disease (IHD) history were independent predictors of LVSD. Logistic regression modelling incorporating these factors improved ROC areas for all natriuretic peptides. The specificity of all natriuretic peptides is enhanced by consideration of these factors. Conclusions: In population screening for definite LVSD, consideration of plasma natriuretic peptide levels together with the presence of major ECG abnormalities and IHD history reduces by a factor of six (in comparison to consideration of plasma natriuretic peptide levels in isolation) the number of subjects requiring echocardiography to detect one case of LVSD (for BNP, 44 falling to seven). Similar improvements were evident for N-ANP and N-BNP. Inclusion of major ECG abnormalities and IHD history improves the performance of any natriuretic peptide used in screening programmes for ruling in undiagnosed LVSD.
Key Words: Heart failure • Natriuretic peptide • Electrocardiogram
Received April 28, 2003; Revised May 21, 2003; Accepted July 31, 2003
Sources of support: National Health Service (NHS) new and emerging applications of technology program.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. W. Troughton and A. M. Richards B-type natriuretic peptides and echocardiographic measures of cardiac structure and function. J. Am. Coll. Cardiol. Img., February 1, 2009; 2(2): 216 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O.W. Nielsen, P.J. Cowburn, A. Sajadieh, J.J. Morton, H. Dargie, and T. McDonagh Value of BNP to estimate cardiac risk in patients on cardioactive treatment in primary care Eur J Heart Fail, December 1, 2007; 9(12): 1178 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Goode, A. L. Clark, J. A. Bristow, K. B. Sykes, and J. G.F. Cleland Screening for left ventricular systolic dysfunction in high-risk patients in primary-care: A cost-benefit analysis Eur J Heart Fail, December 1, 2007; 9(12): 1186 - 1195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Fahey, S Jeyaseelan, C McCowan, E Carr, B. Goudie, S. Pringle, P. Donnan, F. Sullivan, and A. Struthers Diagnosis of left ventricular systolic dysfunction (LVSD): development and validation of a clinical prediction rule in primary care Fam. Pract., December 1, 2007; 24(6): 628 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Q. Khan, O. S. Dhillon, R. J. O'Brien, J. Struck, P. A. Quinn, N. G. Morgenthaler, I. B. Squire, J. E. Davies, A. Bergmann, and L. L. Ng C-Terminal Provasopressin (Copeptin) as a Novel and Prognostic Marker in Acute Myocardial Infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study Circulation, April 24, 2007; 115(16): 2103 - 2110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Goetze, R. Mogelvang, L. Maage, H. Scharling, P. Schnohr, P. Sogaard, J. F. Rehfeld, and J. S. Jensen Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction Eur. Heart J., December 2, 2006; 27(24): 3004 - 3010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. I.W. Galasko, S. C. Barnes, P. Collinson, A. Lahiri, and R. Senior What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination? Eur. Heart J., January 2, 2006; 27(2): 193 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Jeyaseelan, B M Goudie, S D Pringle, P T Donnan, F M Sullivan, and A D Struthers Agreement between community echocardiography and hospital echocardiography in patients suspected of having left ventricular systolic dysfunction Postgrad. Med. J., December 1, 2005; 81(962): 777 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. I.W. Galasko, A. Lahiri, S. C. Barnes, P. Collinson, and R. Senior What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur. Heart J., November 1, 2005; 26(21): 2269 - 2276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.v. Lukowicz, M. Fischer, H.W. Hense, A. Doring, J. Stritzke, G. Riegger, H. Schunkert, and A. Luchner BNP as a marker of diastolic dysfunction in the general population: Importance of left ventricular hypertrophy Eur J Heart Fail, June 1, 2005; 7(4): 525 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Wilkins, G. A. Paul, J. W. Strange, N. Tunariu, W. Gin-Sing, W. A. Banya, M. A. Westwood, A. Stefanidis, L. L. Ng, D. J. Pennell, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study Am. J. Respir. Crit. Care Med., June 1, 2005; 171(11): 1292 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Ng, I. W. Loke, J. E. Davies, S. Geeranavar, K. Khunti, M. A. Stone, D. T. Chin, and I. B. Squire Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1043 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland and K. Goode Natriuretic peptides for heart failure. Fashionable? Useful? Necessary? Eur J Heart Fail, March 15, 2004; 6(3): 253 - 255. [Full Text] [PDF]
|
|